# Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

> **NCT03526250** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 23 (actual)

## Conditions studied

- Advanced Malignant Solid Neoplasm
- Recurrent Childhood Ependymoma
- Recurrent Ewing Sarcoma
- Recurrent Glioma
- Recurrent Hepatoblastoma
- Recurrent Kidney Wilms Tumor
- Recurrent Langerhans Cell Histiocytosis
- Recurrent Malignant Germ Cell Tumor
- Recurrent Malignant Glioma
- Recurrent Medulloblastoma
- Recurrent Neuroblastoma
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Osteosarcoma
- Recurrent Peripheral Primitive Neuroectodermal Tumor
- Recurrent Rhabdoid Tumor
- Recurrent Rhabdomyosarcoma
- Recurrent Soft Tissue Sarcoma
- Refractory Ependymoma
- Refractory Ewing Sarcoma
- Refractory Glioma
- Refractory Hepatoblastoma
- Refractory Langerhans Cell Histiocytosis
- Refractory Malignant Germ Cell Tumor
- Refractory Malignant Glioma
- Refractory Medulloblastoma
- Refractory Neuroblastoma
- Refractory Non-Hodgkin Lymphoma
- Refractory Osteosarcoma
- Refractory Peripheral Primitive Neuroectodermal Tumor
- Refractory Rhabdoid Tumor
- Refractory Rhabdomyosarcoma
- Refractory Soft Tissue Sarcoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Palbociclib
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT03526250
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-13
- **Primary completion:** 2023-03-31
- **Final completion:** 2024-09-30
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03526250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03526250, "Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03526250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*